Topic

Articles

The acquisition boosts Sanofi’s pipeline of immuno-oncology product candidates with a lead candidate in development for treating solid-tumor-type cancers. 

Sanofi Acquires Synthorx for $2.5 Billion

The acquisition aids in the expansion of the Astellas Focus Area approach, which involves the creation of medicines for diseases with high unmet medical needs by identifying combinations of biology, therapeutic modality and technology based on emerging science.

Astellas to Acquire Audentes for $3 Billion

Alkermes plans to advance its investigational new drug-enabling capabilities for lead preclinical assets in the Rodin development candidate portfolio.

Alkermes Acquires Rodin In Deal Worth Up to $950 Million

If successful, the acquisition will boost Recipharm’s global position in the contract development and manufacturing organization (CDMO) market.

Recipharm to Acquire Consort Medical for $649 Million

Through the agreement, Roche will gain full rights to the company’s portfolio of molecules for fibrotic diseases, most notably PRM-151, Promedior’s lead product candidate.

Roche Acquires Promedior Molecule Portfolio For Up to $1.4 Billion

The companies will acquire Orflo’s two flagship products, the Moxi Z and the Moxi Go. 

Gemini, BelHealth Acquire Orflo Technologies

The new company name, Viatris, derives from Latin and represents the company’s main goals. 

Pfizer Announces New Company Name for Mylan and Upjohn Combination

Takeda Pharmaceutical Company has acquired an exclusive global license from COUR Pharmaceuticals for the development and commercialization of an investigational celiac disease therapy.

Takeda Acquires Global License for Investigational Celiac Disease Therapy

Sartorius has signed an agreement for the acquisition of parts of Danaher’s Life Science Portfolio in cash.

Sartorius Signs Acquisition Agreement for Danaher Life Science Platform Business

The therapy received positive results in a randomized, double-blind, placebo-controlled clinical trial in 34 adults with proven celiac disease.

Mergers and Acquisitions